Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous EBV and oncogene-specific cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous EBV and oncogene-specific cytotoxic T lymphocytes are a form of adoptive cell therapy in which a patient's own (autologous) T cells are collected, expanded ex vivo to specifically target antigens from the Epstein-Barr virus (EBV) and relevant oncogenes, then reinfused into the patient. These CTLs are predominantly CD3+ CD8+ cells that recognize and kill EBV-infected or tumorigenic cells expressing viral or oncogenic antigens. The therapy aims to restore or enhance cellular immune responses against chronic active EBV infection or malignancies associated with EBV/oncogene expression. Clinical studies have shown that this approach can resolve symptoms of chronic active EBV infection, normalize anti-EBV antibody titers, reduce viral load in transplant recipients at risk for posttransplantation lymphoproliferative disorders (PTLD), and control tumor growth in preclinical models[1][2][4][5]. The treatment is generally well tolerated with minimal toxicity reported.
- Other names
- autologous EBV-specific cytotoxic T lymphocytesautologous EBV-CTLsautologous Epstein-Barr virus–specific cytotoxic T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)Peptide–Major Histocompatibility Complex class I (pMHC-I) presenting oncogene-derived tumor-associated antigens
Beyond the preview
Go deeper on autologous EBV and oncogene-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous EBV and oncogene-specific cytotoxic T lymphocytes.